• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

AMO completes acquisition of IntraLase


Santa Ana, CA-Advanced Medical Optics Inc. (AMO) has completed its acquisition of IntraLase Corp.

Santa Ana, CA

-Advanced Medical Optics Inc. (AMO) has completed its acquisition of IntraLase Corp.

AMO announced its intention to acquire IntraLase for $808 million in January. IntraLase stockholders approved the deal March 30, and the takeover was finalized April 2. Under the terms of the agreement, AMO paid $25 in cash per share of IntraLase stock and the individually determined cash value per share of outstanding stock options.

“The addition of IntraLase’s state-of-the-art femtosecond laser technology to AMO’s unmatched portfolio of corneal and cataract products allows us to forge a new path for vision care with a full suite of technologies to address a lifetime of refractive needs,” said Jim Mazzo, AMO chairman, president and chief executive officer. He also noted the company’s recently announced acquisition of WaveFront Sciences, developer and manufacturer of a high-resolution aberrometer.

AMO said it intends to leverage the large installed bases of AMO and IntraLase and combined international expansion strategies to establish AMO’s position further as the industry leader in laser diagnostics, flap-creation, and ablation technologies. The acquisition of Intralase also gives AMO entry into the corneal transplant market with the IntraLase-enabled keratoplasty technology.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.